{"Title":"Evolus","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"22","Founded":"","Address":"","Phone":"(949) 284-4555","Web_address":"http://www.evolus.com","Market_cup":"$283.1mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-12.7 mil (last 12 months)","Symbol":"EOLS","Exchange":"NASDAQ","Shares":"5.0","Price_range":"$12.00 - $12.00","Est_volume":"$60.0 mil","Manager":"Cantor/ Mizuho Securities","CO_managers":"SunTrust Robinson Humphrey/ JMP Securities","Exp_to_trade":"2/8/2018","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. We focus on the self-pay aesthetic market and our first product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market."}